Business
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen"). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in
About this update from Santen Pharmaceutical Co., Ltd.
[{"type":"text","content":"YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen"). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia. RemeGen will retain global exclusive rights to RC28-E outside these regions. RemeGen will receive upfront payment of RMB 250 million, development and regulatory milestone payments of up to RMB 520 million, and sales milestone payments of up to RMB 525 million. In addition, RemeGen will be entitled to tiered royalties based on net sales of the product in the licensed territories.","length":1046,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/RemeGen Co., Ltd)","displaySize":"","headline":null,"caption":"(PRNewsfoto/RemeGen Co., Ltd)","className":"","disableSlideshowImg":false,"size":{"original":{"width":192,"height":71,"url":"https://media.zenfs.com/en/prnewswire.com/83868865c97247dad509f61481188c93"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Kxuto_cdaQsvkyxfpl8ttw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/83868865c97247dad509f61481188c93","width":192,"height":71}},"href":"https://mma.prnewswire.com/media/1986829/RemiGen_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"RC28-E is a VEGF/FGF dual-target fusion protein drug for ocular neovascular diseases, independently developed by RemeGen. On May 7, 2025, the Phase II clinical trial results of RC28-E for diabetic macular edema (DME) were presented as an oral report at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting. The study demonstrated that RC28-E significantly improved best-corrected visual acuity (BCVA) and reduced central subfield thickness (CST), and was also well tolerated in patients with DME. In 2023, RemeGen initiated Phase III clinical trials for RC28-E in wet age-related macular degeneration (...